[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX359413B - Metodos de tratamiento de carcinoma hepatocelular. - Google Patents

Metodos de tratamiento de carcinoma hepatocelular.

Info

Publication number
MX359413B
MX359413B MX2016015444A MX2016015444A MX359413B MX 359413 B MX359413 B MX 359413B MX 2016015444 A MX2016015444 A MX 2016015444A MX 2016015444 A MX2016015444 A MX 2016015444A MX 359413 B MX359413 B MX 359413B
Authority
MX
Mexico
Prior art keywords
methods
hepatocellular carcinoma
treatment
taxane
nanoparticles
Prior art date
Application number
MX2016015444A
Other languages
English (en)
Inventor
Yeo Winnie
Wong Nathalie
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX359413B publication Critical patent/MX359413B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención proporciona métodos y composiciones para tratar carcinoma hepatocelular (HCC) por administración de una composición que comprende nanopartículas que comprenden un taxano y una albúmina. La invención también proporciona métodos de tratamiento conjunto para tratar HCC que comprende administrar a un individuo una cantidad eficaz de una composición que comprende nanopartículas que comprenden un taxano y una albúmina, y otro agente tal como un agente que inhibe el desensamblado de microtúbul.
MX2016015444A 2010-03-26 2011-03-25 Metodos de tratamiento de carcinoma hepatocelular. MX359413B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31815310P 2010-03-26 2010-03-26
PCT/US2011/030037 WO2011119988A1 (en) 2010-03-26 2011-03-25 Methods of treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
MX359413B true MX359413B (es) 2018-09-27

Family

ID=44673662

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012010936A MX346861B (es) 2010-03-26 2011-03-25 Metodos de tratamiento de carcinoma hepato celular.
MX2016015444A MX359413B (es) 2010-03-26 2011-03-25 Metodos de tratamiento de carcinoma hepatocelular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012010936A MX346861B (es) 2010-03-26 2011-03-25 Metodos de tratamiento de carcinoma hepato celular.

Country Status (21)

Country Link
US (3) US9370494B2 (es)
EP (2) EP2552438B1 (es)
JP (2) JP5847156B2 (es)
KR (1) KR101786142B1 (es)
CN (2) CN103052385B (es)
AU (1) AU2011230512B2 (es)
BR (1) BR112012024349A2 (es)
CA (2) CA3051495A1 (es)
DK (1) DK2552438T3 (es)
ES (2) ES2675212T3 (es)
HK (2) HK1181665A1 (es)
HR (1) HRP20160609T1 (es)
HU (1) HUE027749T2 (es)
IL (2) IL221886A (es)
LT (1) LT2552438T (es)
MX (2) MX346861B (es)
NZ (1) NZ602382A (es)
PL (1) PL2552438T3 (es)
PT (1) PT2552438T (es)
TW (1) TWI495467B (es)
WO (1) WO2011119988A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
JP5769358B2 (ja) 2005-02-18 2015-08-26 アブラクシス バイオサイエンス， エルエルシー 治療薬の組み合わせおよび投与の様式ならびに併用療法
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
HUE042678T2 (hu) * 2005-08-31 2019-07-29 Abraxis Bioscience Llc Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
CN101605535A (zh) 2006-12-14 2009-12-16 阿布拉科斯生物科学有限公司 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌
JP2010520289A (ja) * 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
PL2155188T3 (pl) * 2007-06-01 2014-03-31 Abraxis Bioscience Llc Sposoby i kompozycje do leczenia nawrotowego raka
WO2010121000A1 (en) 2009-04-15 2010-10-21 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
EP2552438B1 (en) 2010-03-26 2016-05-11 Abraxis BioScience, LLC Methods of treatment of hepatocellular carcinoma
SG184160A1 (en) 2010-03-29 2012-10-30 Abraxis Bioscience Llc Methods of treating cancer
NZ602635A (en) 2010-03-29 2014-12-24 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
KR20140107417A (ko) 2011-12-14 2014-09-04 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN105228612A (zh) 2013-03-12 2016-01-06 阿布拉科斯生物科学有限公司 治疗肺癌的方法
US9962373B2 (en) 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
NZ714273A (en) 2013-05-30 2019-04-26 Nanobiotix Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
WO2015120273A1 (en) * 2014-02-07 2015-08-13 The General Hospital Corporation Differential diagnosis of hepatic neoplasms
PL3229776T3 (pl) 2014-11-25 2023-11-06 Curadigm Sas Kompozycja farmaceutyczna łącząca co najmniej dwie różne nanocząstki i związek farmaceutyczny, jej wytwarzanie i zastosowanie
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai
AR102782A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composición farmacéutica, su preparación y sus usos
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
MX2017015424A (es) 2015-05-28 2018-03-01 Nanobiotix Nanoparticulas para su uso como vacuna terapeutica.
DK3313401T3 (da) 2015-06-29 2021-11-15 Abraxis Bioscience Llc Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer
JP2019529520A (ja) * 2016-10-07 2019-10-17 アブラクシス バイオサイエンス， エルエルシー 胆道がんを処置する方法
US11419842B2 (en) 2016-10-27 2022-08-23 Zhuhai Beihai Biotech Co., Ltd. Neutral pH compositions of Docetaxel and human serum albumin
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CN107828887A (zh) * 2017-10-12 2018-03-23 上海市东方医院 Stmn1基因的用途
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
CA3158764A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
WO2023072755A1 (en) * 2021-10-26 2023-05-04 Lipogems International S.P.A. Microfragmented fat tissue as drug delivery system in liver cancer therapy

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
ES2219646T5 (es) 1993-02-22 2008-11-01 Abraxis Bioscience, Inc. Metodos para la administracion in vivo de compuestos biologicos y composiciones utiles para los mismos.
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HU230338B1 (hu) 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
EP1178786A4 (en) 1999-05-21 2006-03-01 American Bioscience Inc PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE
GB9920548D0 (en) 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
KR20140148502A (ko) 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
JP5769358B2 (ja) 2005-02-18 2015-08-26 アブラクシス バイオサイエンス， エルエルシー 治療薬の組み合わせおよび投与の様式ならびに併用療法
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0615292A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
HUE042678T2 (hu) 2005-08-31 2019-07-29 Abraxis Bioscience Llc Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
BRPI0622006A2 (pt) 2006-08-31 2011-12-20 Abraxis Bioscience Llc usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
JP2010504350A (ja) * 2006-09-19 2010-02-12 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−２００によって調節される遺伝子および経路
CN101605535A (zh) 2006-12-14 2009-12-16 阿布拉科斯生物科学有限公司 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌
JP2010520289A (ja) 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
PL2155188T3 (pl) 2007-06-01 2014-03-31 Abraxis Bioscience Llc Sposoby i kompozycje do leczenia nawrotowego raka
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
WO2009126401A1 (en) 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2367425B1 (en) 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
KR101739598B1 (ko) 2009-03-13 2017-06-08 아브락시스 바이오사이언스, 엘엘씨 티오콜키신 유도체와의 조합 요법
MX2011010673A (es) 2009-04-10 2012-02-21 Abraxis Bioscience Llc Formulaciones de nanoparticulas y usos de las mismas.
WO2010121000A1 (en) 2009-04-15 2010-10-21 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
WO2011025838A1 (en) * 2009-08-25 2011-03-03 Abraxis Bioscience, Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
EP2552438B1 (en) 2010-03-26 2016-05-11 Abraxis BioScience, LLC Methods of treatment of hepatocellular carcinoma
SG184160A1 (en) 2010-03-29 2012-10-30 Abraxis Bioscience Llc Methods of treating cancer
NZ602635A (en) 2010-03-29 2014-12-24 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ708506A (en) 2010-06-02 2016-08-26 Abraxis Bioscience Llc Methods of treating bladder cancer
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
MY166014A (en) 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
KR20140107417A (ko) 2011-12-14 2014-09-04 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter

Also Published As

Publication number Publication date
EP2898884B1 (en) 2018-05-09
DK2552438T3 (en) 2016-07-04
CA2793536A1 (en) 2011-09-29
CN103052385B (zh) 2015-05-27
CN104784121A (zh) 2015-07-22
ES2580135T3 (es) 2016-08-19
WO2011119988A1 (en) 2011-09-29
MX2012010936A (es) 2012-10-10
CN103052385A (zh) 2013-04-17
EP2552438B1 (en) 2016-05-11
US20130115296A1 (en) 2013-05-09
US20160374952A1 (en) 2016-12-29
ES2675212T3 (es) 2018-07-09
KR20130062922A (ko) 2013-06-13
HK1181665A1 (zh) 2013-11-15
CA3051495A1 (en) 2011-09-29
TWI495467B (zh) 2015-08-11
KR101786142B1 (ko) 2017-10-17
BR112012024349A2 (pt) 2016-05-24
EP2898884A1 (en) 2015-07-29
TW201138765A (en) 2011-11-16
US9370494B2 (en) 2016-06-21
EP2552438A1 (en) 2013-02-06
EP2552438A4 (en) 2013-09-04
AU2011230512A1 (en) 2012-10-04
CA2793536C (en) 2019-10-01
US20140079787A1 (en) 2014-03-20
HRP20160609T1 (hr) 2016-09-23
HUE027749T2 (en) 2016-10-28
AU2011230512B2 (en) 2016-09-15
LT2552438T (lt) 2016-09-26
NZ602382A (en) 2014-11-28
JP5847156B2 (ja) 2016-01-20
PT2552438T (pt) 2016-07-07
MX346861B (es) 2017-04-04
JP2013523656A (ja) 2013-06-17
IL247171B (en) 2019-02-28
IL221886A (en) 2016-08-31
HK1212926A1 (zh) 2016-06-24
PL2552438T3 (pl) 2016-12-30
JP2015134825A (ja) 2015-07-27

Similar Documents

Publication Publication Date Title
MX346861B (es) Metodos de tratamiento de carcinoma hepato celular.
MY162903A (en) Methods of treatment of pancreatic cancer
PH12016502066A1 (en) Methods of treating bladder cancer
MX364637B (es) Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
IN2012DN02018A (es)
MY166014A (en) Combination therapy methods for treating proliferative diseases
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
NZ729643A (en) Combination therapy for treating cancer
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
IN2015DN03219A (es)
MX2015011752A (es) Metodos para tratar cancer de pulmon.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2014010749A (es) Composicion ginecologica para tratar la vestibulitis vulvar.
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
BR112012006073A2 (pt) composições e métodos para tratar espasticidade.
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
UA110795C2 (uk) Спосіб лікування раку підшлункової залози
UA101610C2 (ru) Наночастица, которая содержит рапамицин и альбумин, в качестве противоракового агента
EP2575766A4 (en) NEW PHARMACEUTICAL COMPOUNDS